AGENAGENUS INC

Nasdaq agenusbio.com


$ 11.68 $ 3.39 (40.84 %)    

Friday, 26-Apr-2024 15:59:59 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 11.69
$ 8.79
$ 0.00 x 0
$ 0.00 x 0
$ 8.52 - $ 12.14
$ 4.78 - $ 42.60
3,367,371
na
209.19M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-16-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-16-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-15-2016 12-31-2015 10-K
34 11-04-2015 09-30-2015 10-Q
35 08-03-2015 06-30-2015 10-Q
36 05-01-2015 03-31-2015 10-Q
37 03-16-2015 12-31-2014 10-K
38 10-31-2014 09-30-2014 10-Q
39 08-01-2014 06-30-2014 10-Q
40 05-09-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-jpmorgan-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

 small-cap-cancer-drug-developer-agenus-highlights-encouraging-data-from-colorectal-cancer-but-funding-concerns-loom

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC s...

 agenus-announces-updated-phase-1-data-and-progress-on-botbal-development-in-metastatic-mss-colorectal-cancer-updated-phase-1-data-demonstrate-12-month-overall-survival-os-of-71-and-18-month-os-of-62

Company plans to discuss encouraging Phase 2 interim results with the FDA Company plans to submit Phase 2 data to a major medi...

 gold-moves-higher-auddia-shares-surge

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded u...

 why-agenus-shares-are-trading-lower-by-around-17-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of ...

 crude-oil-moves-lower-perion-network-shares-tumble

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded u...

 radcom-lotus-technology-and-3-stocks-to-watch-heading-into-monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as foll...

 agenus-announces-a-1-for-20-reverse-stock-split-of-common-stock-which-will-go-into-effect-on-april-12-2024

Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today an...

 b-riley-securities-maintains-buy-on-agenus-lowers-price-target-to-5

B. Riley Securities analyst Yuan Zhi maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $6 to $5.

 hc-wainwright--co-maintains-buy-on-agenus-maintains-8-price-target

HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and maintains $8 price target.

 agenus-q4-eps-013-misses-005-estimate-sales-8380m-may-not-be-comparable-to-4705m-estimate

Agenus (NASDAQ:AGEN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 1...

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 earnings-preview-for-agenus
Earnings Preview For Agenus
03/13/2024 18:01:01

 agenus-inc-reveals-colorectal-cancer-treatment-results-with-botbal-in-nest-1-study

Agenus Inc. (NASDAQ:AGEN), a leader in developing immunological cancer treatments, today announced results from the NEST-1 stud...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION